All News

No Link Found Between Aluminum in Routine Vaccines and Childhood Disorders: Daily Dose
July 30, 2025

Your daily dose of the clinical news you may have missed.

Why 4 Medical Societies Issued a Joint Advisory on Nutrition and GLP-1 Therapy for Obesity
July 29, 2025

Coauthor of a recent joint advisory, Jonathan Bonnet, MD, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.

Remote Cognitive Screening Platform Expands Access to Early Detection
July 29, 2025

Linus Health is expanding its AI-powered remote cognitive assessment platform, Anywhere, to expand access to early detection of cognitive impairment.

Solriamfetol Treatment Yields Cognitive Gains in Obstructive Sleep Apnea: Daily Dose
July 29, 2025

Your daily dose of the clinical news you may have missed.

Trontinemab Phase 3 Alzheimer Trials to Launch Following Promising Amyloid Clearance Data
July 28, 2025

Data from Roche presented at AAIC 2025 highlight rapid amyloid clearance with investigational antibody and potential of pTau217 as blood-based rule-in and rule-out test.

Low-Value Cancer Screenings Persist Despite Guidelines: Daily Dose
July 28, 2025

Your daily dose of the clinical news you may have missed.

The Obesity–Cardiometabolic Link: Root Causes, Screening, and Primary Care's Role
July 25, 2025

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

In Screening for Dementia, Time Can Tell A Lot: A Conversation with Researcher David Libon, PhD
July 25, 2025

In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.

FDA Extends Review Period for Elinzanetant NDA for Menopausal Vasomotor Symptoms
July 25, 2025

Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.

Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds
July 25, 2025

Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.